📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

In reply: Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors? (2020)

First Author: Bhandari S

Attributed to: Multi-centre Randomized Controlled Trial of angiotensin converting enzyme inhibitor (ACEi) /angiotensin receptor blocker (ARB) - withdrawal in chronic kidney disease – STOP-ACEi-STUDY (SAS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3949/ccjm.87c.01002

PubMed Identifier: 31990646

Publication URI: http://europepmc.org/abstract/MED/31990646

Type: Journal Article/Review

Volume: 87

Parent Publication: Cleveland Clinic journal of medicine

Issue: 1

ISSN: 0891-1150